Infections are a major clinical challenge for type 2 diabetes patients, but little is known about the impact of glycemic control. We used Cox regression analyses to examine the association between baseline and time-varying hemoglobin A 1c (HbA 1c ) values and development of community antiinfective-agent-treated and hospital-treated infections in 69,318 patients with type 2 diabetes diagnosed between 2000 and 2012 in Northern Denmark. Incidence rates were 394/1,000 patient-years for community-treated infections and 63/1,000 patient-years for hospital-treated infections. The adjusted hazard ratios for community-treated infection at an HbA 1c level of ≥10.50%, as compared with 5.50%-<6.49%, were 0.97 (95% confidence interval (CI): 0.94, 1.00) for HbA 1c measured at early baseline, 1.09 (95% CI: 1.03, 1.14) for updated mean 
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Risk of infection among type 2 diabetes patients may depend on glycemic control. Although randomized trials and observational studies have consistently shown that early intensive glycemic control reduces the risk of diabetic microvascular complications by 10%-25% (8) (9) (10) (11) (12) , the effect on infections has not been examined in randomized trials (13) (14) (15) (16) (17) (18) (19) (20) (21) .
Attempts to use observational data to clarify these issues have been hampered by inconsistent results. In addition, hemoglobin A 1c (HbA 1c ) concentration has usually been measured on a single occasion in patients with prevalent diabetes, preventing clarification of the importance of acute hyperglycemia versus longer-term hyperglycemia (22) .
The issue of whether poor glucose control in persons with type 2 diabetes is associated with an increase in community prescriptions for antiinfective agents has not been examined to date. Such data are needed to understand and potentially prevent infections. We therefore undertook a large, population-based study to assess in detail the impact of glycemic control on risk of infectious complications in persons with type 2 diabetes.
METHODS

Study design and data sources
We conducted this population-based cohort study among persons with type 2 diabetes in northern Denmark. The region has 2 million inhabitants, of whom approximately 95% are white. We used the Danish National Patient Registry (DNPR) (23) , the Aarhus University Prescription Database (24) , and the Clinical Laboratory Information System research database (25) to carry out our study. The DNPR contains information on all hospitalizations that have occurred in Denmark since 1977 and on all outpatient and emergency room visits that have occurred since 1995 (23) . The Aarhus University Prescription Database gathers patient-, drug-, and prescriberrelated information. It contains complete data on all prescription medications that have been dispensed from community pharmacies and hospital-based outpatient pharmacies in northern Denmark since 1998 (24) . The Clinical Laboratory Information System database has recorded data on virtually all specimens analyzed in clinical laboratories and general practices in northern Denmark since 2000 (25) . We used the Danish Central Person Registry number to link individual-level data between registries and to collect data on age, sex, marital status, and death (24) .
Identification of patients with type 2 diabetes
We defined incident diagnosis of diabetes as a first prescription for a glucose-lowering drug or a first inpatient or outpatient hospital contact for type 2 diabetes. We identified 70,299 patients who had ever had an incident type 2 diabetes diagnosis first recorded between January 1, 2000, and December 31, 2012, who also had at least one HbA 1c measurement available in the Clinical Laboratory Information System database. We excluded patients who were under age 30 years at the time of their diabetes diagnosis to decrease the probability of including persons with type 1 diabetes (19) . We also excluded 981 females who used metformin monotherapy and had polycystic ovarian disease, as recorded in the DNPR. After these exclusions, 69,318 patients remained in the study cohort.
Data on HbA 1c
We collected available data on all HbA 1c measurements made during the study period. HbA 1c concentration was analyzed in venous blood at each laboratory in northern Denmark using laboratory methods standardized according to the Diabetes Control and Complications Trial assay (26) . We also recorded HbA 1c values using International Federation of Clinical Chemistry standards (26) . The start date of follow-up (the index date) was defined as the date of study subjects' first HbA 1c measurement following their incident diabetes diagnosis.
Data on infection endpoints
Community-treated infection was defined as the first postindex-date redemption of a prescription from a primary care physician for an antiinfective agent for systemic use. Hospitaltreated infection was defined as the first post-index-date occurrence of a hospital inpatient or outpatient clinic contact associated with a primary or secondary discharge diagnosis of infection. We used Anatomical Therapeutic Chemical classification codes (27) to identify prescriptions in the Aarhus University Prescription Database and International Classification of Diseases, Tenth Revision, codes to identify hospital contacts in the DNPR (see the Web Appendix, available at https://academic.oup.com/aje, for codes). We further categorized prescriptions and infection diagnoses into specific groups (see Web Appendix for groups and codes). We followed all patients from their index date to the occurrence of infection, death, emigration, or the end of the study period (December 31, 2012), whichever came first.
Data on covariates
We obtained data for potential confounders, selected a priori from the data sources. These variables included age, sex, marital status, comorbidity, alcoholism-related disorders, and concurrent use of immunosuppressive drugs, oral corticosteroids, statins, and prescriptions for glucose-lowering drugs (by type) before or on the index date. We used all discharge diagnoses recorded in the DNPR on or before the index date to compute a Charlson Comorbidity Index (CCI) score for each patient (28) . Overall comorbidity levels were defined as low (CCI score 0), medium (CCI score 1-2), or high (CCI score ≥3). Duration of known diabetes before the start of follow-up was defined as the difference between the first incident diabetes diagnosis and the index date. Table 1 ). We report incidence rates of community-treated infection and hospital-treated infection per 1,000 patient-years, calculated as the number of patients who contracted an infection divided by the number of patient-years of follow-up.
We used Cox proportional hazards regression analysis to compute hazard ratios and 95% confidence intervals for community-treated infection and hospital-treated infection according to the different HbA 1c exposure groups described above. Hazard ratios were computed both for every 1% increase in HbA 1c level and for the 7 HbA 1c categories, using the HbA 1c level of 5.50%-6.49% as the reference category. We adjusted for age, sex, comorbidity (CCI score), micro-and macrovascular diabetes complications not covered by the CCI, duration of diabetes, alcoholism-related conditions, marital status, concurrent use of statins/corticosteroids/immunosuppressive drugs, calendar period of diabetes diagnosis, and type of glucose-lowering drug regimen as of the index date. We also performed stratified analyses to assess the impact of glycemic control on infection risk in strata of sex, age, comorbidity, and categories of glucose-lowering drugs. We repeated all of the analyses separately for specific infections and specific antiinfective agents for the HbA 1c exposure group showing the clearest association. We also repeated analyses for primary hospital diagnoses of infection only (which are more likely to be community-acquired) and for secondary hospital diagnoses of infection (more likely to be hospital-acquired). Finally, because corticosteroid-induced hyperglycemia may be misclassified as diabetes in some patients, we repeated our overall analysis after excluding all patients who were using corticosteroids within 6 months of the index date.
All analyses were performed using STATA software, version 12 (StataCorp LP, College Station, Texas). The study did not involve any contact with patients or interventions; therefore, according to Danish legislation, it was not necessary to obtain consent. Permission to use health registry data was obtained from the Danish Data Protection Agency.
RESULTS
Among the 69,318 patients with type 2 diabetes, more than half (55%) were male. The median age was 63.3 years (interquartile range, 53.5-72.6 years), the median duration of recorded diabetes before the first HbA 1c measurement was 2.1 months (interquartile range, 0.6-5.8 months), and 73% were taking glucose-lowering drugs at the time of their first HbA 1c measurement (Web Table 1 ). The mean HbA 1c value at baseline was 7.50% (standard deviation, 1.9), 35% of patients had an HbA 1c value of 7.50% or more, and a small proportion (4%) had an HbA 1c value less than 5.50%. Compared with patients with a reference HbA 1c value of 5.50%-6.49%, patients with higher HbA 1c values at baseline were more likely to be male, were younger, had less comorbidity and less statin use, and were more likely to use glucose-lowering drugs at onset (except those with HbA 1c values greater than or equal to 10.50%) (Web Table 1 ).
A total of 48,442 patients (70%) received systemic antiinfective agents in the community during a follow-up period comprising 123,113 patient-years at risk, yielding an overall incidence rate of 393.5 (95% confidence interval (CI): 390.0, 397.0) per 1,000 patient-years (Table 1) . A total of 16,227 patients (23%) experienced hospital-treated infection over a follow-up period comprising 259,524 patient-years at risk, yielding an incidence rate of 62.5 (95% CI: 61.6, 63.5) per 1,000 patient-years (Table 2) .
Early baseline HbA 1c concentration
The incidence rates of community-treated infections and hospital-treated infections appeared to decrease with increasing baseline HbA 1c values (Tables 1 and 2 ). After adjustment for variables associated with a high baseline HbA 1c concentration (including younger age and less comorbidity), we observed no increase in the rates of communitytreated infections and hospital-treated infections per 1% increase in baseline HbA 1c (adjusted hazard ratios were 0.99 (95% CI: 0.99, 1.00) and 1.01 (95% CI: 1.00, 1.02), respectively). Compared with the reference HbA 1c value of 5.50%-6.49%, a baseline HbA 1c value less than 5.50% was associated with increased rates of community-treated infection (adjusted hazard ratio (HR) = 1.06, 95% CI: 1.01, 1.12) and hospital-treated infection (adjusted HR = 1.29, 95% CI: 1.19, 1.40), while adjusted hazard ratios were close to unity in categories of increasing baseline HbA 1c values (Figures 1  and 2 ).
Updated mean and updated time-weighted mean HbA 1c concentration
For measures of updated mean HbA 1c concentration, there was a clearer association between increasing HbA 1c values and incidence rates of community-treated and hospital-treated infection (Tables 1 and 2 ). For every 1% increase in updated mean HbA 1c values, the adjusted hazard ratio for communitytreated infection was 1.01 (95% CI: 1.01, 1.02), and for hospital-treated infection it was 1.06 (95% CI: 1.04, 1.07). Compared with an updated mean HbA 1c level of 5.50%-6.49%, rates of community-treated infection were increased both for updated mean HbA 1c values less than 5.50% and for increasing values greater than or equal to 6.50% (Table 1, Figure 1) . For hospital-treated infection, the association was stronger, and an updated mean HbA 1c concentration greater than or equal to 10.50% was associated with an adjusted hazard ratio of 1.55 (95% CI: 1.42, 1.71). For updated time-weighted mean HbA 1c values, rates of community-treated infection increased by 2% (adjusted HR = 1.02, 95% CI: 1.01, 1.03) with each 1% increase, and rates of hospital-treated infection increased by 6% (adjusted HR = 1.06, 95% CI: 1.05, 1.07). Infection rates for updated time-weighted mean HbA 1c followed a similar gradient as for updated mean HbA 1c , with the highest rate being observed in patients with HbA 1c values greater than or equal to 10.50% for both community-treated and hospital-treated infections (Table 1 and Figure 1 ). of 5.50%-7.49% and increased monotonically with increasing HbA 1c levels (Tables 1 and 2 ). For every 1% increase in the latest updated HbA 1c value, the rate of community-treated infection increased by 3% (adjusted HR = 1.03, 95% CI: 1.02, 1.04) and the rate of hospital-treated infection increased by 6% (adjusted HR = 1.06, 95% CI: 1.05, 1.07). An association with risk of infection was observed, particularly for latest updated HbA 1c values of 8.50% or higher, reaching adjusted hazard ratios of 1.19 (95% CI: 1.14, 1.26) for community-treated infection and 1.64 (95% CI: 1.51, 1.79) for hospitaltreated infection in patients with HbA 1c levels greater than or equal to 10.50% as compared with 5.50%-6.49% (Figures 1 and 2) .
Association of latest updated HbA 1c value with specific community-treated and hospital-treated infections Web Table 2 shows adjusted hazard ratios for specific community-and hospital-treated infection groups associated with every 1% increase in latest updated HbA 1c and by different categories of latest updated HbA 1c . For communitytreated infections, the strongest associations with each 1% increase in the latest updated HbA 1c value were observed for the broad-spectrum antibiotics cephalosporins (adjusted HR = 1.38); for dicloxacillin/flucloxacillin, which is normally used to treat Staphylococcus aureus infections (adjusted HR = 1.07); for quinolones (adjusted HR = 1.13); and for antifungal therapy (adjusted HR = 1.13). Adjusted hazard ratios per 1% increase in latest updated HbA 1c values were particularly increased for abscesses (HR = 1.17), skin infections (HR = 1.14), and infections of the central nervous system (HR = 1.10) but also for fungal infections (HR = 1.11), viral infections (HR = 1.07), septicemia (HR = 1.08), upper respiratory tract infections (HR = 1.07), urinary tract infections (HR = 1.04), and eye and ear infections (HR = 1.09) (Web Table 2 ).
Subgroup and sensitivity analyses
The relationship between increased risk of infections and higher HbA 1c levels was found consistently in all subgroups (shown for latest updated HbA 1c levels in Table 3 ). The impact of a high HbA 1c level seemed to be strongest in patients with microvascular complications. Otherwise, the hazards of infection associated with poor glucose control were similar in patients with and without comorbidity, in all age groups, and in patients using and not using glucose-lowering drugs at baseline (Table 3) .
When we examined primary and secondary hospital diagnoses of infection as separate outcomes, the associations with HbA 1c followed a similar pattern as the overall hospital infection estimates (Web Tables 3-5) .
Seven percent of patients (5,153/69,318) had used oral corticosteroids within 6 months of their diabetes diagnosis. After exclusion of these patients, analyses on the remaining cohort generated risk estimates identical to the original estimates (e.g., per 1% increase in latest updated HbA 1c value, the adjusted hazard ratio was 1.03 (95% CI: 1.02, 1.04) for community-treated infection and 1.06 (95% CI: 1.04, 1.07) for hospital-treated infection).
DISCUSSION
This population-based study of patients with type 2 diabetes suggests that average glycemic control, and in particular current glycemic control-assessed as the latest updated HbA 1c level-is important for the risk of infection in type 2 diabetes, particularly for hospital-treated infections. In contrast, there seemed to be no strong association between baseline HbA 1c levels obtained soon after the start of therapy and later infections.
Our findings underscore the importance of the present guidelines for HbA 1c targets (29) . Our results indicate that for infectious complications, current hyperglycemia as measured by the single latest HbA 1c level is important, supporting the hypothesis of an acute and reversible impact of hyperglycemia on infections. There may be differences in the mechanisms at play for infection and micro-and macrovascular complications. For vascular diabetes complications, Lind et al. (22) suggested that mean or updated mean HbA 1c values in general are more important than single HbA 1c measurements.
Evidence from similar cohort studies on the association between glycemic control over time and risk of infection in type 2 diabetes is limited (15) (16) (17) (18) 30) . Our study corroborates findings from a smaller Dutch study of general practices (30) . In that study, Bartelink et al. (30) reported no overall difference in mean HbA 1c levels in type 2 diabetes patients with and without infection, whereas patients who presented with an infection at some point during follow-up showed higher HbA 1c levels in that period compared with periods without any infection. Other studies have assessed singlepoint HbA 1c values, focusing on specific selected infections. Those investigators reported increased risks associated with poor glycemic control for bloodstream infections (16, 17) , pneumonia requiring hospitalization (18) , tuberculosis (19) , vaginitis and balanitis (20) , and urinary tract infection (21) . The Copenhagen City Heart Study, a study of the Copenhagen general population, assessed plasma glucose at baseline and found a particularly increased risk of urinary tract infections and skin infections with increased glucose levels (15) . This is in line with our results. Among patients undergoing surgical cardiac procedures, acute hyperglycemia is a known predictor of wound infections (3, 31) , and randomized trials have shown that intensive insulin treatment may reduce the risk of subsequent sepsis (32) or wound infection (31) .
In our study, we found increased risk of infection at HbA 1c levels below 5.50%, in addition to high levels. A similar J-shaped association has been observed between HbA 1c and mortality (33) and cardiovascular disease (34) . We observed that the patient group with HbA 1c values less than 5.50% was younger than other patients, more likely to have high comorbidity (notable given their younger age), and more likely to have alcoholism-related conditions (Web Table 1 ). We speculate that some of these patients had mild or borderline diabetes detected during clinical workup and treatment for other severe conditions, and that the apparently higher infection risk associated with very low HbA 1c might be explained by unmeasured comorbidity and other risk factors in these patients. Other researchers (35, 36) observing similar J-or U-shaped outcome curves have suggested that patients with very low HbA 1c levels may have more comorbidity and another "phenotype" of type 2 diabetes. Alternatively, causal and detrimental effects of hypoglycemia may be at play. Hypoglycemia thus might lead to adverse outcomes through sympathoadrenal activation, thrombogenesis, vasoconstriction, and the release of inflammatory mediators and cytokines (36) . Carson et al. (37) reported that an HbA 1c concentration as low as <4% is a marker of unfavorable red blood cell factors and is suggestive of underlying inflammation and liver disease. Additional research with more detailed clinical and biomarker data than our study possessed is needed to investigate the exact mechanisms.
In our study, the setting of the Danish health-care system permitted the use of a population-based design with inclusion of all patients who had hospital-or drug-treated type 2 diabetes within a well-defined region and a homogenous population, as well as complete follow-up and availability of laboratory data for assessment of glycemic control. These features largely eliminated the selection problems prevalent in smaller follow-up studies based on limited numbers of participants. By using both prescription and hospital-based data, we were able to identify all infections requiring medical attention, unlike previous studies, which often focused exclusively on infections treated in the hospital.
Our study also had limitations. First, we defined incident diabetes on the basis of prescriptions and hospital diagnoses in Danish registries, not exact measurements of hyperglycemia. For example, we missed type 2 diabetes patients treated with lifestyle interventions, and we relied on HbA 1c measurements as ordered by physicians in the course of routine clinical care. Second, patients with poor glycemic control versus good glycemic control may have a lower threshold of antiinfective or hospital treatment when infection is suspected (surveillance bias), leading to overestimation of the association. Third, we cannot exclude the possibility of reverse causality in some patients in clinical practice-that is, latent infection's leading to increasing HbA 1c levels. Fourth, most of our confounders were measured at the index date, and values for some of them may have changed during follow-up. However, follow-up was short due to early outcome events in many patients, and factors that may be affected by exposure to high HbA 1c levels during follow-up should not be adjusted for. Fifth, we did not have information on certain infection risk factors that may have altered HbA 1c values, such as blood transfusions or enteral or parenteral nutrition, which could have led to HbA 1c misclassification in some patients. Sixth, as in any observational study, other imperfectly measured, unmeasured, or unknown factors may have affected the observed associations, including high body mass index, smoking, low physical activity, and other adverse lifestyle and socioeconomic measures. Nonetheless, we were able to adjust for a wide range of medical conditions closely associated with these adverse factors, likely reducing their confounding effect. Finally, we had no genetic data available with which to examine any genetic predisposition for insulin resistance, diabetes, and infections.
It has been hypothesized that increased risk of infection may be mediated primarily by long-term chronic hyperglycemia via chronic tissue inflammation or development of other complications, which in turn increase risk of infection (3, 6, 7) . As has been reviewed elsewhere (3), numerous in vitro studies have demonstrated that hyperglycemia may impair the innate immune system, inhibit adaptive immunity, and interfere with complement cascade through glycosylation of immune proteins (6, 7) . Such processes may underlie our finding of increased risk of infection associated with current hyperglycemia. Alternatively, unmeasured factors associated with high HbA 1c levels, such as high body mass index and lower socioeconomic status-both of which are documented risk factors for infection (38, 39) -may explain our findings in part. A large proportion of patients with very high HbA 1c levels (≥10.50%) used neither glucose-lowering nor statin treatment. Such poor glucose control may be a marker of decreased compliance with preventive therapies in general, including use of other cardiovascular drugs and possibly vaccinations.
In summary, our population-based cohort study provides evidence that among patients with type 2 diabetes, current hyperglycemia is associated with increased risk of communitytreated and hospital-treated infections. The findings from this study suggest that infections in persons with type 2 diabetes may be prevented with appropriate and consistent glycemic control.
